PRIMARY STUDY
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial
Key Findings: Among patients with diabetes who were given gemigliptin, compared to placebo there were significant improvements in biomarkers of vascular and renal function, including improved levels of liver fatty acid-binding protein (L-FABP)/Cr.
Type of Study: Clinical Trial
Study Sample Size: 182
Study Result: Positive
Research Location(s): Thailand
Year of Pub: 2021
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Ligands Studied: Insulin, Pro-inflammatory cytokines
Citation: Trakarnvanich T, et al. Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial. J Diabetes Res. 2021; 2021:7382620. doi: 10.1155/2021/7382620
Authors: Trakarnvanich T, Satirapoj B, Suraamornkul S, Chirananthavat T, Sanpatchayapong A, Claimon T
